CRISPR Therapeutics and Spotify Technologies have been top performers in the market this year, with CRISPR benefiting from progress with its leading candidates. Cathie Wood’s Ark Invest has seen success with these picks, despite some criticisms. CRISPR’s pipeline shows promise, particularly with CTX310 targeting heart disease risk factors. Spotify’s expanding ecosystem and move towards profitability are driving its success.

CRISPR Therapeutics, a gene-editing biotech company, has seen an 85% increase in shares this year due to promising pipeline programs like CTX310 for lowering LDL cholesterol and triglycerides. Other programs like CTX112 for blood cancers and CTX320 for heart health are also showing potential. The company’s approach could lead to better outcomes than current therapies.

Spotify Technologies, the leading music streaming platform, has a top global market share and has seen shares rise by 50% this year. The company’s deep network effect and brand name have helped maintain its lead. Initiatives like podcasting and AI-driven features are driving growth and improving margins, with plans to reach 1 billion users by 2030.

Investors should consider the potential of CRISPR Therapeutics and Spotify Technologies, as both companies show strong growth prospects in their respective fields. While there are risks involved, the success of their pipeline programs and expansion efforts indicate a positive future outlook. Consider the track record and potential of these companies before making investment decisions.

Read more at Nasdaq: 2 Soaring Cathie Wood Stocks to Buy and Hold